Business Context and Reporting Period
This Form 8-K Current Report was filed by Synaptogenix, Inc. (not TAO Synergies Inc.) on January 22, 2021, regarding events occurring on January 21, 2021. The company is an emerging growth company focused on clinical trials for Alzheimer's disease.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of equity securities.
- Gross Proceeds: Approximately $14,000,000.
- Offering Price: $1.50 per share of Common Stock and Warrants.
- Securities Issued:
- 9,335,533 shares of Common Stock and/or Pre-Funded Warrants (exercise price $0.01).
- Series E Warrants to purchase 9,335,533 shares (exercise price $2.1275, 12-month term).
- Series F Warrants to purchase 9,335,533 shares (exercise price $1.725, 5-year term).
- Placement Agent Fees: 10% cash fee plus 10% of shares sold in Broker Warrants (exercise price $1.725, 5-year term).
- Use of Proceeds: Completion of Phase 2 clinical trial for Alzheimer's disease, potential future trials, and general corporate purposes.
Material Changes
The filing reports the entry into a Material Definitive Agreement and unregistered sales of equity securities. There are no comparative financial metrics (revenue, profit, cash flow) provided in this specific filing as it details a capital raise event rather than periodic financial results.
Outlook, Risks, and Contingencies
- Registration Obligations: The Company must file a registration statement for the resale of securities within 30 days of closing and use commercially reasonable efforts to have it declared effective within 120 days (or 150 days if delayed by the SEC).
- Liquidated Damages: The Company may incur liquidated damages if it fails to meet specific registration deadlines or if certain other events occur under the Registration Rights Agreement.
- Regulatory Status: Securities were sold under Section 4(2) of the Securities Act and/or Regulation D exemptions.
Investor Verification Checklist
- Verify the actual closing date and final gross proceeds received.
- Confirm the dilution impact of the 9,335,533 new shares and associated warrants on existing shareholders.
- Monitor the filing of the registration statement for resale of securities within the required 30-day window.
- Review the full text of the Securities Purchase Agreement and Registration Rights Agreement (Exhibits 10.1 and 10.2) for specific liquidated damages clauses.
- Track progress of the Phase 2 Alzheimer's disease clinical trial funded by these proceeds.